Literature DB >> 30310429

Stroke Prevention in Atrial Fibrillation - The Use of NOACs in Everyday Clinical Practice.

Gheorghe-Andrei Dan1, Adrian Catalin Buzea2.   

Abstract

Non-antivitamin K oral anticoagulants (NOACs) have recently emerged as a new class of antithrombotic drugs. Four large-scale, randomised controlled trials (RCT) accredited dabigatran, rivaroxaban and edoxaban with evident advantages for stroke prevention in atrial fibrillation (AF) compared with warfarin. The superiority concerns not only the manageability but also the antithrombotic efficacy and safety. Aspects of real-life clinical experience with NOAC for stroke prevention in AF are analysed in an attempt to underline some practical differences. If at present the individualisation of the NOAC class drugs is still a subject of debate it is probable that in the near future we will be able to adapt the drug and dosages to individual patient's profile.

Entities:  

Keywords:  NOAC (non-antivitamin K oral anticoagulants); abigatran; apixaban; atrial fibrillation; darucizumab; edoxaban; ivaroxaban; oral anticoagulants (OAC); stroke prevention; warfarin

Year:  2015        PMID： 30310429      PMCID： PMC6159476          DOI： 10.15420/ecr.2015.10.2.76

Source DB:  PubMed          Journal:  Eur Cardiol        ISSN： 1758-3756


  22 in total

1.  Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.

Authors:  Jonathan Douxfils; François Mullier; Séverine Robert; Christian Chatelain; Bernard Chatelain; Jean-Michel Dogné
Journal:  Thromb Haemost       Date:  2012-03-22       Impact factor: 5.249

2.  Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).

Authors:  Bernard Vrijens; Marc J Claeys; Victor Legrand; Eef Vandendriessche; Frans Van de Werf
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

3.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

4.  Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Authors:  David J Graham; Marsha E Reichman; Michael Wernecke; Rongmei Zhang; Mary Ross Southworth; Mark Levenson; Ting-Chang Sheu; Katrina Mott; Margie R Goulding; Monika Houstoun; Thomas E MaCurdy; Chris Worrall; Jeffrey A Kelman
Journal:  Circulation       Date:  2014-10-30       Impact factor: 29.690

5.  Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.

Authors:  Gregory Y H Lip; Flemming Skjøth; Lars Hvilsted Rasmussen; Torben Bjerregaard Larsen
Journal:  J Am Coll Cardiol       Date:  2015-03-11       Impact factor: 24.094

6.  Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.

Authors:  Gregory Y H Lip; Andreas Clemens; Herbert Noack; Jorge Ferreira; Stuart J Connolly; Salim Yusuf
Journal:  Thromb Haemost       Date:  2013-12-11       Impact factor: 5.249

7.  Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.

Authors:  François Laliberté; Michel Cloutier; Winnie W Nelson; Craig I Coleman; Dominic Pilon; William H Olson; C V Damaraju; Jeffrey R Schein; Patrick Lefebvre
Journal:  Curr Med Res Opin       Date:  2014-04-02       Impact factor: 2.580

8.  The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.

Authors:  Stuart J Connolly; Lars Wallentin; Michael D Ezekowitz; John Eikelboom; Jonas Oldgren; Paul A Reilly; Martina Brueckmann; Janice Pogue; Marco Alings; John V Amerena; Alvaro Avezum; Iris Baumgartner; Andrzej J Budaj; Jyh-Hong Chen; Antonio L Dans; Harald Darius; Giuseppe Di Pasquale; Jorge Ferreira; Greg C Flaker; Marcus D Flather; Maria Grazia Franzosi; Sergey P Golitsyn; David A Halon; Hein Heidbuchel; Stefan H Hohnloser; Kurt Huber; Petr Jansky; Gabriel Kamensky; Matyas Keltai; Sung Soon Kim; Chu-Pak Lau; Jean-Yves Le Heuzey; Basil S Lewis; Lisheng Liu; John Nanas; Razali Omar; Prem Pais; Knud E Pedersen; Leopoldo S Piegas; Dimitar Raev; Pal J Smith; Mario Talajic; Ru San Tan; Supachai Tanomsup; Lauri Toivonen; Dragos Vinereanu; Denis Xavier; Jun Zhu; Susan Q Wang; Christine O Duffy; Ellison Themeles; Salim Yusuf
Journal:  Circulation       Date:  2013-06-14       Impact factor: 29.690

Review 9.  Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.

Authors:  Jonathan Douxfils; François Mullier; Claire Loosen; Christian Chatelain; Bernard Chatelain; Jean-Michel Dogné
Journal:  Thromb Res       Date:  2012-09-21       Impact factor: 3.944

10.  Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.

Authors:  Ajay K Kakkar; Iris Mueller; Jean-Pierre Bassand; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Werner Hacke; Gregory Y H Lip; Lorenzo G Mantovani; Alexander G G Turpie; Martin van Eickels; Frank Misselwitz; Sophie Rushton-Smith; Gloria Kayani; Peter Wilkinson; Freek W A Verheugt
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.